Author: John Pinching

Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions

Lead Alzheimer’s candidate shows clear biological effects and antidepressant potential

Deal covers up to five candidates including SB36 as company expands global pipeline

Study to explore mechanism behind novel oral therapy for muscle‑sparing weight loss

Financing and global licensing deal to accelerate phase 2b development of AP306